Alnylam Surges 2.8% on 148% Volume Spike Ranks 161st in Market Activity

On July 30, 2025, Alnylam Pharmaceuticals (ALNY) recorded a trading volume of $0.7 billion, a 148.43% surge from the prior day, placing it 161st in the stock market. The stock closed with a 2.80% gain.

Alnylam recently secured European Union approval for its drug AMVUTTRA, a milestone that strengthens its pipeline of RNA interference therapeutics. The approval, combined with its existing four FDA-approved treatments for rare genetic diseases, underscores the company’s leadership in the biopharmaceutical sector. This regulatory progress is expected to bolster investor confidence in its long-term growth potential.

The company announced a webcast for its second-quarter 2025 financial results, scheduled for July 31, 2025. The upcoming earnings report is likely to draw heightened attention from investors, given Alnylam’s recent operational milestones and its focus on expanding its therapeutic portfolio. The timing of the release suggests a strategic effort to align with market volatility and highlight key financial metrics.

A backtesting strategy involving the top 500 stocks by daily trading volume yielded a 166.71% return from 2022 to July 30, 2025, significantly outperforming the benchmark’s 29.18%. This approach generated an excess return of 137.53% and a compound annual growth rate of 31.89%, demonstrating the potential of volume-driven short-term positioning in capturing market liquidity and sentiment.